Literature DB >> 11398166

Cell proliferative activity and expression of cell-cell adhesion factors (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) in sarcomatoid renal cell carcinoma.

K Kuroiwa1, T Konomoto, J Kumazawa, S Naito, M Tsuneyoshi.   

Abstract

BACKGROUND AND OBJECTIVES: Sarcomatoid RCC (renal cell carcinoma) is an uncommon, but not rare, neoplasm which has been shown to have a much worse prognosis than common RCC. The current study was designed to investigate the association of proliferative activity and cell-cell adhesion molecules with sarcomatoid RCC.
METHODS: Proliferative activity (Ki-67 labeling index) and expression of cell-cell adhesion associated molecules (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) were examined using immunohistochemical techniques in 11 cases of sarcomatoid RCC.
RESULTS: In six patients with sarcomatous component more than 50%, five were died within 24 month after diagnosis. The expression of these molecules within the carcinomatous and sarcomatous components of sarcomatoid RCC was compared. The mean Ki-67 labeling index in the sarcomatous components (12.6%) is statistically higher than in the carcinomatous components (3.7%) (P < 0.05). The expressions of E-cadherin, and alpha-, beta-, and gamma-catenin were statistically decreased in the sarcomatous components compared to the carcinomatous components. However, no differences were observed regarding p120 immunostaining.
CONCLUSIONS: The findings of the current study suggest that the range of the sarcomatous component may be a prognostic factor in RCC, and the malignant behavior of sarcomatoid RCC is due to high cell proliferative activity and decreased expressions of E-cadherin and alpha-, beta-, and gamma-catenin in the sarcomatous component. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398166     DOI: 10.1002/jso.1082

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Authors:  Sumanta K Pal; Jeremy O Jones; Courtney Carmichael; Junmi Saikia; Joanne Hsu; Xueli Liu; Robert A Figlin; Przemyslaw Twardowski; Clayton Lau
Journal:  Urol Oncol       Date:  2012-05-17       Impact factor: 3.498

2.  Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.

Authors:  Brian Shuch; Jonathan Said; Jeffrey C LaRochelle; Ying Zhou; Gang Li; Tobias Klatte; Frederic Pouliot; Fairooz F Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

3.  RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Authors:  Sumanta K Pal; Miaoling He; Tommy Tong; Huiqing Wu; Xueli Liu; Clayton Lau; Jin-Hui Wang; Charles Warden; Xiwei Wu; Sabina Signoretti; Toni K Choueiri; Jose A Karam; Jeremy O Jones
Journal:  Mol Cancer Res       Date:  2014-09-02       Impact factor: 5.852

4.  Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Authors:  Mark Bi; Siming Zhao; Jonathan W Said; Maria J Merino; Adebowale J Adeniran; Zuoquan Xie; Cayce B Nawaf; Jaehyuk Choi; Arie S Belldegrun; Allan J Pantuck; Harriet M Kluger; Kaya Bilgüvar; Richard P Lifton; Brian Shuch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-10       Impact factor: 11.205

5.  Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.

Authors:  Megan M Merrill; Christopher G Wood; Nizar M Tannir; Rebecca S Slack; Kara N Babaian; Eric Jonasch; Lance C Pagliaro; Zachary Compton; Pheroze Tamboli; Kanishka Sircar; Louis L Pisters; Surena F Matin; Jose A Karam
Journal:  Urol Oncol       Date:  2015-02-17       Impact factor: 3.498

6.  Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation.

Authors:  Ashwini K Esnakula; Tammey J Naab; William Green; Babak Shokrani
Journal:  BMJ Case Rep       Date:  2013-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.